New Pfizer AIDS drug approval delayed

(Reuters) - Pfizer received a so-called approvable letter from the Food and Drug Administration for the twice-a-day pill that is the first drug designed to keep the HIV virus that causes AIDS from entering healthy immune cells. Older AIDS medicines attack the virus itself.



The company said it was in discussions with the FDA to address the agency's outstanding questions and finalize the product labeling as soon as possible.


Read more at Reuters.com Government Filings News

Pfizer, Glaxo Are Poised to Emulate Genentech in Breakthroughs on Cancer

(Bloomberg) -- The best time to buy Pfizer Inc. and
GlaxoSmithKline Plc may be now, with their shares at a five-year
low relative to earnings and about two dozen treatments in
development designed to attack cancer.

Pfizer, the largest pharmaceutical company, is valued at
12.3 times profit, far from its peak of 72 times in 1998. Glaxo,
the second-biggest drugmaker, has a price-earnings ratio of 13.3,
the lowest in at least five years.


Read more at Bloomberg Exclusive News